<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01210989</url>
  </required_header>
  <id_info>
    <org_study_id>NAFLD- Hepaguard</org_study_id>
    <nct_id>NCT01210989</nct_id>
  </id_info>
  <brief_title>Trial of Hepaguard® in Adults With Nonalcoholic Steatohepatitis</brief_title>
  <official_title>A Randomized,Placebo-controlled,Double-blind Trial of Phyllanthus Urinaria (Hepaguard®) in Adults With Nonalcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nonalcoholic fatty liver disease is one of the most common chronic liver diseases worldwide.
      Nonalcoholic steatohepatitis (NASH) is the active form of the disease which runs a
      progressive course and may result in liver cirrhosis and liver cancer. However, there is yet
      proven treatment for this disorder. In cell line and animal studies, we have shown that
      Phyllanthus urinaria can ameliorate NASH by reducing oxidative stress and lipid accumulation.
      Phyllanthus (Hepaguard) has been used widely by patients with chronic liver diseases, but the
      efficacy in NASH has not been confirmed in humans.

      This study is divided into two parts. In part 1, 60 patients with histology-confirmed NASH
      will be randomized to receive Hepaguard or placebo for 24 weeks to test the efficacy.
      Endpoints will be assessed at week 24. The aim of part 2 is to test the durability of
      Hepaguard. Forty patients originally on Hepaguard will be randomized again to continue
      Hepaguard for another 24 weeks or stop the treatment. The endpoints at week 48 will be
      further analyzed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in affluent
      countries. Patients with nonalcoholic steatohepatitis (NASH), a severe form of NAFLD
      characterized by ballooning, lobular inflammation and liver fibrosis, have increased
      mortality rate and risk of cardiovascular disease. Besides, some patients progress to
      cirrhosis and may even develop hepatocellular carcinoma. In long-term studies, up to 13% of
      NAFLD patients died of hepatic complications.(1)

      Owing to westernization of lifestyle, NAFLD is also increasing dramatically in Asia. In a
      population screening study in Shanghai using ultrasonography, 15% of adult Chinese was found
      to suffer from NAFLD.(2) Among Chinese patients with NAFLD, significant necroinflammation and
      liver fibrosis are not uncommon.(3-5) These patients also often have progression of liver
      fibrosis with time.(6)

      Since NASH is closely related to type 2 diabetes and obesity, a logical approach would be to
      improve these metabolic parameters.(7, 8) Observational studies suggest that regular exercise
      and weight reduction benefit NASH patients. At present, there is no registered drug for the
      treatment of NASH. Although insulin sensitizers such as pioglitazone and rosiglitazone may
      improve the metabolic profile and hepatic necroinflammation,(9, 10) the effects are not
      durable.(11) Weight gain and cardiovascular complications also limit the use of these
      agents.(12, 13) More effective and better tolerated treatment is urgently needed.

      Phyllanthus urinaria (Hepaguard®) is commonly used by patients with various chronic liver
      diseases.(14-16) Phyllanthus has excellent safety profile. In in vitro and in vivo models of
      NAFLD, Phyllanthus reduces hepatic steatosis, necroinflammation and fibrosis.(16) Oxidative
      stress and lipid accumulation are ameliorated. Whether the same beneficial effects apply to
      humans is unclear.

      References:

        1. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The
           natural history of nonalcoholic fatty liver disease: a population-based cohort study.
           Gastroenterology 2005;129:113-21.

        2. Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, Li F, Chen SY. Prevalence of and risk factors
           for fatty liver in a general population of Shanghai, China. J Hepatol 2005;43:508-14.

        3. Wong VW, Chan HL, Hui AY, Chan KF, Liew CT, Chan FK, Sung JJ. Clinical and histological
           features of non-alcoholic fatty liver disease in Hong Kong Chinese. Aliment Pharmacol
           Ther 2004;20:45-9.

        4. Wong VW, Wong GL, Chim AM, Tse AM, Tsang SW, Hui AY, Choi PC, Chan AW, So WY, Chan FK,
           Sung JJ, Chan HL. Validation of the NAFLD fibrosis score in a Chinese population with
           low prevalence of advanced fibrosis. Am J Gastroenterol 2008;103:1682-8.

        5. Wong VW, Wong GL, Tsang SW, Hui AY, Chan AW, Choi PC, Chim AM, Chu S, Chan FK, Sung JJ,
           Chan HL. Metabolic and histological features of non-alcoholic fatty liver disease
           patients with different serum alanine aminotransferase levels. Aliment Pharmacol Ther
           2009;29:387-96.

        6. Hui AY, Wong VW, Chan HL, Liew CT, Chan JL, Chan FK, Sung JJ. Histological progression
           of non-alcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther
           2005;21:407-13.

        7. Wong VW, Hui AY, Tsang SW, Chan JL, Tse AM, Chan KF, So WY, Cheng AY, Ng WF, Wong GL,
           Sung JJ, Chan HL. Metabolic and adipokine profile of Chinese patients with nonalcoholic
           fatty liver disease. Clin Gastroenterol Hepatol 2006;4:1154-61.

        8. Wong VW, Hui AY, Tsang SW, Chan JL, Wong GL, Chan AW, So WY, Cheng AY, Tong PC, Chan FK,
           Sung JJ, Chan HL. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in
           Chinese patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther
           2006;24:1215-22.

        9. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A,
           Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan
           GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with
           nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307.

       10. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin
           P, Lacorte JM, Bernhardt C, Bruckert E, Grimaldi A, Poynard T. Rosiglitazone for
           nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled
           Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology
           2008;135:100-10.

       11. Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, Borg B, Loomba R, Liang
           TJ, Premkumar A, Hoofnagle JH. The effects of discontinuing pioglitazone in patients
           with nonalcoholic steatohepatitis. Hepatology 2007;46:424-9.

       12. Balas B, Belfort R, Harrison SA, Darland C, Finch J, Schenker S, Gastaldelli A, Cusi K.
           Pioglitazone treatment increases whole body fat but not total body water in patients
           with non-alcoholic steatohepatitis. J Hepatol 2007;47:565-70.

       13. Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM. Adverse
           cardiovascular events during treatment with pioglitazone and rosiglitazone: population
           based cohort study. BMJ 2009;339:b2942.

       14. Wang M, Cheng H, Li Y, Meng L, Zhao G, Mai K. Herbs of the genus Phyllanthus in the
           treatment of chronic hepatitis B: observations with three preparations from different
           geographic sites. J Lab Clin Med 1995;126:350-2.

       15. Chan HL, Sung JJ, Fong WF, Chim AM, Yung PP, Hui AY, Fung KP, Leung PC. Double-blinded
           placebo-controlled study of Phyllanthus urinaris for the treatment of chronic hepatitis
           B. Aliment Pharmacol Ther 2003;18:339-45.

       16. Shen B, Yu J, Wang S, Chu ES, Wong VW, Zhou X, Lin G, Sung JJ, Chan HL. Phyllanthus
           urinaria ameliorates the severity of nutritional steatohepatitis both in vitro and in
           vivo. Hepatology 2008;47:473-83.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histologic NAFLD activity score</measure>
    <time_frame>week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ALT normalization</measure>
    <time_frame>week 24 &amp; week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic endpoints</measure>
    <time_frame>Weeks 12, 24, 36 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in magnetic resonance spectroscopy</measure>
    <time_frame>Weeks 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver stiffness measurement</measure>
    <time_frame>Weeks 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of NASH and liver fibrosis</measure>
    <time_frame>Weeks 12, 24, 36 and 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Nonalcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Hepaguard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phyllanthus urinaria</intervention_name>
    <description>Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance. At week 24, subjects receiving active Hepaguard will be randomized (1:1) to continue Hepaguard for another 24 weeks or stop treatment.</description>
    <arm_group_label>Hepaguard</arm_group_label>
    <other_name>Hepaguard®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or above,

          -  Histologic NAFLD activity score 3,

          -  Written informed consent

        Exclusion Criteria:

          -  Positive hepatitis B surface antigen, or anti-hepatitis C virus antibody, or
             histologic features of an alternative liver disease,

          -  Alcohol consumption above 30g per week in men or 20g per week in women,

          -  Serum alanine aminotransferase above 10 times the upper limit of normal,

          -  Liver decompensation,

          -  Evidence of hepatocellular carcinoma currently or in the past 5 years,

          -  Type 1 diabetes or insulin treatment,

          -  Use of investigational drugs in the last 12 weeks,

          -  Terminal illness or cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cheng Suen Man Shook Hepatitis Center, Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong SAR</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005 Jul;129(1):113-21.</citation>
    <PMID>16012941</PMID>
  </reference>
  <reference>
    <citation>Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, Li F, Chen SY. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol. 2005 Sep;43(3):508-14.</citation>
    <PMID>16006003</PMID>
  </reference>
  <reference>
    <citation>Wong VW, Chan HL, Hui AY, Chan KF, Liew CT, Chan FK, Sung JJ. Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese. Aliment Pharmacol Ther. 2004 Jul 1;20(1):45-9.</citation>
    <PMID>15225170</PMID>
  </reference>
  <reference>
    <citation>Wong VW, Wong GL, Chim AM, Tse AM, Tsang SW, Hui AY, Choi PC, Chan AW, So WY, Chan FK, Sung JJ, Chan HL. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol. 2008 Jul;103(7):1682-8. doi: 10.1111/j.1572-0241.2008.01933.x. Epub 2008 Jul 4.</citation>
    <PMID>18616651</PMID>
  </reference>
  <reference>
    <citation>Wong VW, Wong GL, Tsang SW, Hui AY, Chan AW, Choi PC, Chim AM, Chu S, Chan FK, Sung JJ, Chan HL. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. Aliment Pharmacol Ther. 2009 Feb 15;29(4):387-96. doi: 10.1111/j.1365-2036.2008.03896.x. Epub 2008 Nov 17.</citation>
    <PMID>19035982</PMID>
  </reference>
  <reference>
    <citation>Hui AY, Wong VW, Chan HL, Liew CT, Chan JL, Chan FK, Sung JJ. Histological progression of non-alcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther. 2005 Feb 15;21(4):407-13.</citation>
    <PMID>15709991</PMID>
  </reference>
  <reference>
    <citation>Wong VW, Hui AY, Tsang SW, Chan JL, Tse AM, Chan KF, So WY, Cheng AY, Ng WF, Wong GL, Sung JJ, Chan HL. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006 Sep;4(9):1154-61. Epub 2006 Aug 14.</citation>
    <PMID>16904946</PMID>
  </reference>
  <reference>
    <citation>Wong VW, Hui AY, Tsang SW, Chan JL, Wong GL, Chan AW, So WY, Cheng AY, Tong PC, Chan FK, Sung JJ, Chan HL. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006 Oct 15;24(8):1215-22.</citation>
    <PMID>17014580</PMID>
  </reference>
  <reference>
    <citation>Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006 Nov 30;355(22):2297-307.</citation>
    <PMID>17135584</PMID>
  </reference>
  <reference>
    <citation>Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin P, Lacorte JM, Bernhardt C, Bruckert E, Grimaldi A, Poynard T; LIDO Study Group. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008 Jul;135(1):100-10. doi: 10.1053/j.gastro.2008.03.078. Epub 2008 Apr 8.</citation>
    <PMID>18503774</PMID>
  </reference>
  <reference>
    <citation>Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, Borg B, Loomba R, Liang TJ, Premkumar A, Hoofnagle JH. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007;46:424-9. 12. Balas B, Belfort R, Harrison SA, Darland C, Finch J, Schenker S, Gastaldelli A, Cusi K. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. J Hepatol 2007;47:565-70.</citation>
  </reference>
  <reference>
    <citation>Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ. 2009 Aug 18;339:b2942. doi: 10.1136/bmj.b2942.</citation>
    <PMID>19690342</PMID>
  </reference>
  <reference>
    <citation>Wang M, Cheng H, Li Y, Meng L, Zhao G, Mai K. Herbs of the genus Phyllanthus in the treatment of chronic hepatitis B: observations with three preparations from different geographic sites. J Lab Clin Med. 1995 Oct;126(4):350-2.</citation>
    <PMID>7561442</PMID>
  </reference>
  <reference>
    <citation>Chan HL, Sung JJ, Fong WF, Chim AM, Yung PP, Hui AY, Fung KP, Leung PC. Double-blinded placebo-controlled study of Phyllanthus urinaris for the treatment of chronic hepatitis B. Aliment Pharmacol Ther. 2003 Aug 1;18(3):339-45.</citation>
    <PMID>12895219</PMID>
  </reference>
  <reference>
    <citation>Shen B, Yu J, Wang S, Chu ES, Wong VW, Zhou X, Lin G, Sung JJ, Chan HL. Phyllanthus urinaria ameliorates the severity of nutritional steatohepatitis both in vitro and in vivo. Hepatology. 2008 Feb;47(2):473-83.</citation>
    <PMID>18157836</PMID>
  </reference>
  <reference>
    <citation>Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006 Oct;44(4):865-73.</citation>
    <PMID>17006923</PMID>
  </reference>
  <reference>
    <citation>Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005 Jun;41(6):1313-21.</citation>
    <PMID>15915461</PMID>
  </reference>
  <reference>
    <citation>Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007 Apr;45(4):846-54.</citation>
    <PMID>17393509</PMID>
  </reference>
  <reference>
    <citation>Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006 Jun;43(6):1317-25.</citation>
    <PMID>16729309</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2010</study_first_submitted>
  <study_first_submitted_qc>September 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2010</study_first_posted>
  <last_update_submitted>February 20, 2014</last_update_submitted>
  <last_update_submitted_qc>February 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Henry LY Chan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

